Prelude Therapeutics, led by CEO Kris Vaddi, recently closed its third funding round. | PHOTO COURTESY OF PRELUDE THERAPEUTICS
Prelude Therapeutics gets $50M Series C funding
WILMINGTON – Prelude Therapeutics, a private life sciences start-up company, announced Aug. 24 that it has closed a $50 million Series C financing round, continuing its explosive growth in only four years.
The new funds come from Prelude’s two existing institutional investors, including New York-based OrbiMed Advisors LLC, and a new investor, Boston-based Fidelity Management & Research Company LLC. When combined with its previous investment rounds, it has secured a total investment of $145 million after starting with $5 million in start-up funds.
